Back to Search
Start Over
Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR)
- Source :
- Anaesthesia, critical care & pain medicine, Vol. 37, no. 4, p. 379-389 (2018), Anaesthesia Critical Care and Pain Medicine, 37 (4
- Publication Year :
- 2018
-
Abstract
- The French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Haemostasis and Thrombosis (GFHT) in collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR) drafted up-to-date proposals for the management of antiplatelet therapy in patients undergoing elective invasive procedures. The proposals were discussed and validated by a vote; all proposals but one could be assigned with a high strength. The management of antiplatelet therapy is based on their indication and the procedure. The risk of bleeding related to the procedure can be divided into high, moderate and low categories depending on the possibility of performing the procedure in patients receiving antiplatelet agents (none, monotherapy and dual antiplatelet therapy respectively). If discontinuation of antiplatelet therapy is indicated before the procedure, a last intake of aspirin, clopidogrel, ticagrelor and prasugrel 3, 5, 5 and 7 days before surgery respectively is proposed. The thrombotic risk associated with discontinuation should be assessed according to each specific indication of antiplatelet therapy and is higher for patients receiving dual therapy for coronary artery disease (with further refinements based on a few well-accepted items) than for those receiving monotherapy for cardiovascular prevention, for secondary stroke prevention or for lower extremity arterial disease. These proposals also address the issue of the potential role of platelet functional tests and consider management of antiplatelet therapy for regional anaesthesia, including central neuraxial anaesthesia and peripheral nerve blocks, and for coronary artery surgery.<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published
- Subjects :
- medicine.medical_specialty
Prasugrel
Blood Loss, Surgical
030204 cardiovascular system & hematology
Critical Care and Intensive Care Medicine
Perioperative Care
Coronary artery disease
03 medical and health sciences
0302 clinical medicine
medicine
Humans
030212 general & internal medicine
Intensive care medicine
Aspirin
business.industry
Bleeding
Antiplatelet agents
Généralités
Thrombosis
General Medicine
Perioperative
medicine.disease
Clopidogrel
Hemostasis, Surgical
Discontinuation
Anesthesiology and Pain Medicine
Elective Surgical Procedures
Anesthesia
Surgery
business
Regional anaesthesia
Ticagrelor
Platelet Aggregation Inhibitors
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Anaesthesia, critical care & pain medicine, Vol. 37, no. 4, p. 379-389 (2018), Anaesthesia Critical Care and Pain Medicine, 37 (4
- Accession number :
- edsair.doi.dedup.....b9cbc7949c6fa4ae422ff0ac9c709601